Acrivon Therapeutics (ACRV) accounting chief sells shares for taxes

Rhea-AI Filing Summary

Acrivon Therapeutics, Inc. (ACRV) reported that Chief Accounting Officer Katharine Peterson sold 101 shares of common stock on 2026-08-18 at $2.01 per share. According to the company’s disclosure, these shares were sold automatically to satisfy mandatory tax withholding upon vesting of restricted stock units, and she now holds 18,033 shares directly.

Insider Trade Summary

Net Seller: 101 shares

Net Sell 1 txn

Insider Peterson Katharine

Role Chief Accounting Officer

Sold 101 shs ($203.01)

Type	Security	Shares	Price	Value
Sale	Common Stock F1	101	$2.01	$203.01

Holdings After Transaction: Common Stock — 18,033 shares (Direct)

Footnotes (1)

1. F1. Shares sold automatically to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units.

Key Figures

Shares sold: 101 shares of Common Stock Sale price: $2.01 per share Shares held after transaction: 18,033 shares +1 more

4 metrics

Shares sold 101 shares of Common Stock Automatic sale on 2026-08-18 to satisfy mandatory tax withholding

Sale price $2.01 per share Price for the 101 shares of Acrivon Therapeutics common stock sold

Shares held after transaction 18,033 shares Direct ownership by Katharine Peterson following the sale

Net shares sold 101 shares Net change in buy/sell activity reported in this Form 4

Key Terms

restricted stock units, mandatory tax withholding, open market or private transaction

3 terms

restricted stock units financial

"upon vesting of restricted stock units"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

mandatory tax withholding financial

"sold automatically to satisfy the mandatory tax withholding requirement"

open market or private transaction financial

"Sale in open market or private transaction"

FAQ

What insider transaction did ACRV disclose for Katharine Peterson?

Acrivon Therapeutics disclosed that Chief Accounting Officer Katharine Peterson sold 101 shares of common stock on 2026-08-18 at $2.01 per share, in an automatic sale to cover mandatory tax withholding upon vesting of restricted stock units.

How many ACRV shares does Katharine Peterson hold after this transaction?

After the reported tax-withholding sale, Katharine Peterson directly holds 18,033 shares of Acrivon Therapeutics common stock, as stated in the filing.

Was the ACRV insider sale by Katharine Peterson a discretionary trade?

The filing states the 101 shares were sold automatically to satisfy mandatory tax withholding upon vesting of restricted stock units, indicating the transaction was tied to an equity award vesting event rather than a discretionary open-market decision.

What was the price for Katharine Peterson’s ACRV share sale?

The 101 shares of Acrivon Therapeutics common stock were sold at a price of $2.01 per share, according to the reported transaction details.

Does this ACRV Form 4 involve derivatives or options exercises?

No. The reported transaction involves Common Stock only, with no derivative transactions or option exercises shown in the derivative summary of the Form 4.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 08/20/2026 - 04:10 PM Accepted by SEC EDGAR 08/20/2026 - 04:10 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Peterson Katharine

(Last) (First) (Middle)

C/O ACRIVON THERAPEUTICS, INC.

480 ARSENAL WAY, SUITE 100

(Street)

WATERTOWN MASSACHUSETTS 02472

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Acrivon Therapeutics, Inc. [ ACRV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Accounting Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/18/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/18/2026		S(1)		101	D	$2.01	18,033	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Shares sold automatically to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units.

	/s/ Adam D. Levy, Attorney-in-Fact	08/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)